-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Ziresovir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1422500-60-4.gif)
| Category | Respiratory syncytial Virus (RSV) |
| CAS | 1422500-60-4 |
| Description | Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species. |
Product Information
| Synonyms | Ziresovir|1422500-60-4|AK0529|UNII-XCF42D7AG4|RO-0529|XCF42D7AG4|CHEMBL4468815|AK-0529|4-(4-(((3-Aminooxetan-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine 1,1-dioxide|N-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-2H-1lambda6,4-benzothiazepin-4-yl)-6-methylquinazolin-4-amine|Ziresovir [INN]|N-((3-Aminooxetan-3-yl)methyl)-2-(1,1-dioxido-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)-6-methylquinazolin-4-amine|N-((3-aminooxetan-3-yl)methyl)-2-(1,1-dioxo-3,5-dihydro-2H-1lambda6,4-benzothiazepin-4-yl)-6-methylquinazolin-4-amine|N-[(3-Aminooxetan-3-yl)methyl]-2-(1,1-dioxido-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)-6-methylquinazolin-4-amine|SCHEMBL14704847|BDBM50516304|DB15145|AZ171068|HY-109142|CS-0086934|A937667|4-(4-(((3-Aminooxetan-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydro-1H-1lambda6,4-benzothiazepine-1,1-dione|4-(4-(((3-Aminooxetan-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine1,1-dioxide|4-Quinazolinamine, N-((3-amino-3-oxetanyl)methyl)-2-(2,3-dihydro-1,1-dioxido-1,4-benzothiazepin-4(5H)-yl)-6-methyl-|N-((3-Amino-3-oxetanyl)methyl)-2-(2,3-dihydro-1,1-dioxido-1,4-benzothiazepin-4(5H)-yl)-6-methyl-4-quinazolinamine |
| Molecular Weight | 439.53 |
| Molecular Formula | C22H25N5O3S |
| Canonical SMILES | CC1=CC2=C(C=C1)N=C(N=C2NCC3(COC3)N)N4CCS(=O)(=O)C5=CC=CC=C5C4 |
| Boiling Point | 745.4±70.0 °C at 760 mmHg |
| Flash Point | 404.6±35.7 °C |
| Purity | ≥98% (HPLC) |
| Density | 1.4±0.1 g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White to off-white (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 740 |
| Exact Mass | 439.16781085 |
| Index Of Refraction | 1.679 |
| Target | EC50: 3 nM (RSV F) |
| Vapor Pressure | 0.0±2.5 mmHg at 25°C |
| XLogP3-AA | 1.8 |
